Anti-p14 ARF (P16) AntibodyDatasheet
|Name:||Anti-p14 ARF (P16) Antibody|
|Description:||Rabbit polyclonal antibody to p14 ARF (P16) .|
|Applications:||WB, IHC, IF|
|Dilutions:||WB 1:500 - 1:2000, IHC 1:50 - 1:200, IF 1:50 - 1:200|
|Immunogen:||A synthetic peptide of human CDKN2A|
|Formulation:||PBS with 0.02% sodium azide, 50% glycerol, pH7.3.|
|Storage:||Store at -20℃. Avoid freeze / thaw cycles.|
Target (Information from UniProt)
|Function:||Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.|
|Tissue Specificity:||Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific.|
|Involvement in Disease:||Melanoma, cutaneous malignant 2: A malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites.
Familial atypical multiple mole melanoma-pancreatic carcinoma syndrome: An inherited cancer predisposition syndrome characterized by an increased risk of developing malignant melanoma and/or pancreatic cancer. Mutation carriers within families may develop either or both types of cancer.
Melanoma-astrocytoma syndrome: Characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma.
|Sequence Similarities:||Belongs to the CDKN2 cyclin-dependent kinase inhibitor family.|
|Post-Translational Modification:||Phosphorylation seems to increase interaction with CDK4.|
|Cellular Location:||Cytoplasm. Nucleus.|
Western blot analysis of extracts of various cell lines, using CDKN2A antibody.
Immunofluorescence analysis of A549 cells using CDKN2A antibody.